COVID-19 vaccine (mRNA)

The mRNA COVID-19 vaccine is a type of vaccine that uses messenger RNA to instruct cells to produce a protein unique to the SARS-CoV-2 virus, triggering an immune response and providing protection against the disease. This vaccine has been crucial in reducing severe illness, hospitalization, and death from COVID-19.

Several studies have explored the safety and adverse effects of mRNA vaccines. Anaphylaxis is a rare but serious allergic reaction that can occur after vaccination, with specific risk factors including a history of allergies or previous anaphylactic reactions. Serious adverse events, such as myocarditis and pneumonitis, have been reported in some cases, particularly following the second dose. However, these events are generally rare and the benefits of vaccination outweigh the risks for most individuals.

The mRNA COVID-19 vaccine is closely linked to discussions on vaccine development and the broader landscape of mRNA technology. It also intersects with research on myocarditis, as both the virus and the vaccine have been associated with this condition, though the risk from the vaccine is lower than that from the infection itself.

While these studies provide valuable insights, more research is needed to fully understand long-term effects and rare adverse events.

Sources

• mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation. (PMID:36689047)
• Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. (PMID:36055877)
• COVID-19 mRNA Vaccine-induced Pneumonitis. (PMID:34707048)
• The Covid-19 Vaccine-Development Multiverse. (PMID:32663910)
• Do COVID-19 viral infection and its mRNA vaccine carry an equivalent risk of myocarditis? Review of the current evidence, insights, and future directions. (PMID:37399904)
• Self-assembled mRNA vaccines. (PMID:33400957)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._